Hematological and biochemical changes due to anti-hepatitis C virus therapy

Objective The aim of the study was to assess the hematological and biochemical changes in patients who have received anti-hepatitis C virus (HCV) therapy before treatment and follow-up after 3 months of treatment as regards the advantages and disadvantages through a follow up of the studied patients. Background There is a dramatic improvement in HCV therapy following the introduction of oral medicines that directly inhibit the replication cycle of HCV, so the follow up of patients who are receiving therapy before and 6 months after treatment is mandatory to choose the best drug for each patient with the least side effects. Patients and methods This study was done on 200 patients admitted to the Kafr El-Sheikh Hepatology Center diagnosed as HCV-infected patients. Those patients were classified according to the Child classification as Child A score 6. Of them, 100 patients received sofosbuvir + ledipasvir and another 100 patients received sofosbuvir + daclatasvir, respectively. All patients were subjected to the following investigations before and 6 months after treatment: complete blood count, biochemical investigations including serum albumin, alanine transaminase, aspartate transaminase, random blood sugar, blood urea, serum creatinine, total and direct bilirubin, and alkaline phosphatase, thyroid-stimulating hormone level, alpha-fetoprotein, and antinuclear antibody. Results All the previous laboratory investigations were done to all 200 patients, recorded and compared before treatment and 6 months after treatment. Conclusion Ledipasvir and sofosbuvir for 8 weeks or 12 weeks is a highly effective treatment option for the treatment of hepatitis C-infected patients and give best results more than sofosbuvir and daclatasvir.